ClinicalTrials.gg
RecruitingNCT07851857PROTECT-HNUpdated Oct 5, 2026

Prophylactic Antibiotic Duration in Head and Neck Cancer Surgery (PROTECT-HN Trial)

A Phase 3 interventional study of Ampicillin/Sulbactam 24-Hour Postoperative Prophylaxis and Ampicillin/Sulbactam 7-Day Postoperative Prophylaxis in Surgical Wound Infection, Head and Neck Neoplasms and Oral Cancer Neoplasms, sponsored by AC Camargo Cancer Center. Recruiting at 1 site in Brazil. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-05.

Sponsored by AC Camargo Cancer Center · Phase 3, Interventional, and Prevention

How we know

From the registry’s dates

  • Registered 1 year 3 months after the study started (first participant enrolled May 2025, registered Sep 2026).
  • Started May 2025; still recruiting 1 year 5 months later.
Updated Oct 5, 2026Title changedNewly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 15 studies in Surgical Wound Infection with a site in Brazil — 2 open to participants now, 2 under way, 2 of them phase 3. Surgical Wound Infection · Brazil.

Planned enrollment
11th of 15
80 · median 124
Started
2025
the only one that year
Phase 3
5 of 15
2 open now
Registered
15th of 15
by date
Lead sponsor
1 of 15
AC Camargo Cancer Center

Among the 15 studies in Surgical Wound Infection with a site in Brazil, this one is the 11th largest by planned enrollment, is the only one that started in 2025, is one of 5 in phase 3, and was the 15th registered.

Surgical Wound Infection

747 studies on the registry are indexed under Surgical Wound Infection; 152 are open to participants now.

Browse Surgical Wound Infection studies →

Open to participants now

2 of the 15 studies in Surgical Wound Infection with a site in Brazil are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in Brazil have not opened yet or have stopped. Only those recruiting at a site in Brazil →

Who these studies take

Of the 85 Surgical Wound Infection studies recruiting now, 62 (73%) set no upper age limit and 16 (19%) stop at 75 or younger; 12 take children under 18; 14 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Surgical Wound Infection with a site in Brazil, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn whether giving antibiotics for 7 days after surgery, instead of the usual 24 hours, lowers the chance of wound infection in adults having major surgery for mouth or throat cancer. This includes operations that rebuild the area with tissue taken from another part of the body (free-flap reconstruction).

The main question it aims to answer is:

Does a 7-day course of antibiotics after surgery lower the number of patients who get a surgical wound infection within 30 days, compared with the standard 24-hour course?

Other questions are:

Does the longer course shorten the time spent in the intensive care unit and in the hospital? Does it lower the number of emergency room visits, hospital readmissions, and hospital costs within 30 days? Is the longer course safe, and does it cause more side effects?

Researchers will compare two groups. Both groups receive the same antibiotic (ampicillin/sulbactam) through a vein before and during surgery. After surgery, one group continues the antibiotic for 24 hours (the current standard), and the other group continues it for 7 days, or until they go home if that is sooner.

Participants will:

Be assigned by chance (like flipping a coin) to one of the two groups Follow the hospital's usual care before surgery, including mouthwash, antiseptic body wash, and nasal ointment for 5 days Receive the antibiotic according to their group Be followed for 30 days after surgery to check for wound infection, other complications, return visits, and readmissions

Read the detailed description

Background and Rationale

Surgical site infection (SSI) is a common and serious complication of major head and neck cancer surgery. Operations such as mandibulectomy, pharyngolaryngectomy, and major glossectomy, and procedures that need microvascular free-flap or pedicled flap reconstruction, expose the neck to bacteria from the oral cavity and upper aerodigestive tract for many hours. Several other factors add to the risk: tumor-associated oral dysbiosis, long operative times, flap ischemia, dead space, previous radiotherapy, malnutrition, tobacco and alcohol use, and tracheostomy. As a result, reported SSI rates in these operations range from 20% to 50%. That is much higher than expected for clean-contaminated procedures and closer to the rates seen in infected procedures. SSI is linked to fistula, flap failure, reoperation, longer hospital stays, delays in adjuvant treatment, and higher costs.

Centers for Disease Control and Prevention (CDC) and World Health Organization (WHO) guidelines advise against continuing antibiotic prophylaxis after surgery ends. However, these guidelines do not address the specific risk factors of head and neck reconstruction, and these patients are underrepresented in the trials behind them. Practice varies widely: in one survey of microvascular surgeons, 5 days of prophylaxis was the most common duration, and some authors recommend 7 days for free-flap cases. Retrospective studies disagree about whether longer courses help, and no randomized evidence exists. Data from low- and middle-income countries, where SSI rates are higher, are especially limited.

At the study institution, SSI indicators have been collected prospectively since 2014. SSI rates in major and free-flap head and neck procedures stayed between 33% and 50.9%. This was true even after the prophylactic regimen was changed from clindamicin plus ceftriaxone to ampicillin/sulbactam in 2022, and after a preoperative decolonization protocol was introduced. In a previous prospective cohort of 401 patients, the overall SSI rate was 41.9%. This trial tests whether extending postoperative prophylaxis lowers SSI and length of stay in this high-risk group.

Study Design

Single-center, pragmatic, open-label, randomized, parallel-group superiority trial. The trial is pragmatic because both regimens are already used in clinical practice. Blinding is not feasible because the arms differ in how long the postoperative antibiotic is given.

Randomization

Patients are allocated 1:1 using a maximum tolerated imbalance (MTI) procedure with an imbalance limit of 3. When the limit is reached, the next patient is assigned to the smaller arm. This lowers the predictability of allocation while keeping the arms balanced. Allocation is generated dynamically in REDCap after enrollment, and patients do not cross over between arms.

Standardized Perioperative Care (Both Arms)

Preoperative decolonization for 5 days: 0.12% chlorhexidine oral rinse three times a day, 2% chlorhexidine body wash once a day, and nasal mupirocin three times a day.

Preoperative consultations with nursing, nutrition (with supplementation when needed), and oral medicine.

In the operating room: 2-minute skin antisepsis of the resection and donor sites with 2% chlorhexidine or 10% povidone-iodine, plus oral and pharyngeal cleansing with 0.12% chlorhexidine.

The first antibiotic dose is given at anesthesia induction, 10 to 60 minutes before skin incision, and redosed every 4 hours during surgery.

Data Collection

Data are collected from the electronic medical record with a standardized case report form and entered in REDCap. Variables include:

Demographics and lifestyle: age, sex, smoking (pack-years), alcohol use. Clinical data: comorbidities, American Society of Anesthesiologists Physical Status Classification System, Body Mass Index.

Tumor data: site, histology, UICC-TNM stage, prior radiotherapy or chemotherapy.

Surgical data: main procedure, type of reconstruction, flap ischemia time (from pedicle ligation to completion of the anastomoses), operative time (from skin incision to dressing), salvage surgery, and perioperative blood transfusion.

Cost Analysis

Costs are taken from the institution's patient-level billing database (Base de Atendimento) for the index surgical admission. Direct costs are materials, drugs, and professional fees. Indirect costs are allocated by absorption costing and include idle capacity. The analysis follows the Brazilian Ministry of Health guidelines for economic evaluation, takes the payer perspective, and uses micro-costing. Unit prices come from public procurement references: BEC/SP and the Ministry of Health Health Price Database.

Statistical Analysis

Analyses follow the intention-to-treat principle and are done in R and Python. Categorical variables are compared with the chi-square test and continuous variables with Student's t-test. Multivariable analysis uses Cox proportional hazards models, with the proportional hazards assumption checked by Schoenfeld residuals.

Sample Size The sample size was calculated for the primary outcome (30-day SSI) as a comparison of two independent proportions. The SSI rate in the control group was assumed to be 43%, based on the institutional prospective cohort of patients undergoing major head and neck surgery. An SSI rate of 12% was expected in the intervention group, which is an absolute reduction of 31 percentage points.

With a two-sided significance level of 5% and 80% power, at least 32 evaluable patients per group are needed. Allowing for an estimated 10% loss to follow-up, the sample was set at 40 patients per group, for a total of 80 participants. The calculation was done in G*Power, version 3.1.9.7.

Interim Safety Analysis

A safety analysis will be done once 50% of the planned patients have completed 30 days of follow-up. Adverse events are graded using CTCAE. The two arms will be compared for serious treatment-related complications, including infections other than SSI (such as Clostridioides difficile), drug toxicity, and allergic reactions. If the difference in serious adverse event rates between the arms is greater than 20%, early termination or protocol changes will be considered together with the institutional Infection Prevention and Control Service.

03

Conditions studied

  • Surgical Wound Infection
  • Head and Neck Neoplasms
  • Oral Cancer Neoplasms
  • Pharyngeal Neoplasms

Keywords

  • Antibiotic Prophylaxis
  • Extended Antibiotic Prophylaxis
  • Surgical Site Infection
  • Head and Neck Surgery
  • Length of Stay
  • Hospital Costs
  • Pragmatic Clinical Trial
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18 years or older
  • Diagnosis of cancer of the oral cavity or pharynx
  • Scheduled for major head and neck surgery (e.g., mandibulectomy, pharyngolaryngectomy, major glossectomy) and/or reconstruction with a microvascular free flap or pedicled flap
  • Communication between the primary tumor site and the neck during surgery (direct exposure of the neck to oral or pharyngeal contents)
  • Signed

Exclusion criteria

Exclusion Criteria:

  • Known allergy to ampicillin/sulbactam, penicillins, or other beta-lactam antibiotics
  • Infected surgical field, or active infection needing therapeutic antibiotics at the time of surgery
  • Refusal to participate
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
80 participants (estimated)

Study arms

  • Active comparator
    Standard Prophylaxis (24 Hours)

    Participants receive the institutional standard antibiotic prophylaxis with ampicillin/sulbactam: 3 g IV at anesthesia induction (10 to 60 minutes before skin incision), 3 g IV every 4 hours during surgery, and 3 g IV every 6 hours for 24 hours after surgery. All participants also complete the institutional preoperative decolonization protocol for 5 days before surgery (chlorhexidine oral rinse, chlorhexidine body wash, and nasal mupirocin).

    Drug: Ampicillin/Sulbactam 24-Hour Postoperative Prophylaxis

  • Experimental
    Extended Prophylaxis (7 Days)

    Participants receive ampicillin/sulbactam 3 g IV at anesthesia induction (10 to 60 minutes before skin incision) and 3 g IV every 4 hours during surgery, the same as the standard group. After surgery, the antibiotic continues at 3 g IV every 6 hours for 7 days, or until hospital discharge if that is sooner. All participants also complete the institutional preoperative decolonization protocol for 5 days before surgery (chlorhexidine oral rinse, chlorhexidine body wash, and nasal mupirocin). Interventions: ☑ Ampicillin/Sulbactam 7-Day Postoperative Prophylaxis

    Drug: Ampicillin/Sulbactam 7-Day Postoperative Prophylaxis

Interventions

  • DrugAmpicillin/Sulbactam 24-Hour Postoperative Prophylaxis

    Participants receive the institutional standard antibiotic prophylaxis with ampicillin/sulbactam: 3 g IV at anesthesia induction (10 to 60 minutes before skin incision), 3 g IV every 4 hours during surgery, and 3 g IV every 6 hours for 24 hours after surgery. All participants also complete the institutional preoperative decolonization protocol for 5 days before surgery (chlorhexidine oral rinse, chlorhexidine body wash, and nasal mupirocin).

  • DrugAmpicillin/Sulbactam 7-Day Postoperative Prophylaxis

    Participants receive ampicillin/sulbactam 3 g IV at anesthesia induction (10 to 60 minutes before skin incision) and 3 g IV every 4 hours during surgery, the same as the standard group. After surgery, the antibiotic continues at 3 g IV every 6 hours for 7 days, or until hospital discharge if that is sooner. All participants also complete the institutional preoperative decolonization protocol for 5 days before surgery (chlorhexidine oral rinse, chlorhexidine body wash, and nasal mupirocin).

06

What researchers measure

Primary outcomes

  1. Incidence of Surgical Site Infection

    Proportion of participants in each arm who develop a surgical site infection (SSI) within 30 days after surgery. SSI is diagnosed when at least one of the following is present: (1) purulent drainage from the incision; (2) a positive culture from fluid or tissue at the incision obtained with aseptic technique; or (3) a diagnosis of SSI by the attending surgeon or physician. The groups are compared using the chi-square test (intention-to-treat analysis).

    Time frame: From surgery through postoperative day 30

Secondary outcomes

  1. Secondary Outcome Measure [*]

    Number of days the participant stays in the intensive care unit (ICU) during the surgical admission.

    Time frame: From surgery through hospital discharge, up to 30 days after surgery

  2. Hospital Length of Stay

    Number of days from hospital admission for surgery to hospital discharge.

    Time frame: From hospital admission through discharge, up to 30 days after surgery

  3. Hospital Readmission Rate

    Proportion of participants readmitted to the hospital for clinical or surgical complications within 30 days after discharge from the surgical admission. Planned admissions for adjuvant treatment (such as placement of a chemotherapy catheter) are not counted.

    Time frame: Within 30 days after hospital discharge

  4. Emergency Department Visit Rate

    Proportion of participants who make at least one unscheduled emergency department visit after discharge from the surgical admission.

    Time frame: Within 30 days after surgery

  5. Total Hospitalization Cost

    Total cost of the surgical admission, in Brazilian reais (BRL), including direct costs (materials, drugs, professional fees) and indirect costs (allocated by absorption costing). Micro-costing is used, from the payer perspective.

    Time frame: From hospital admission through discharge, up to 30 days after surgery

  6. Incidence of Serious Adverse Events

    Proportion of participants with serious treatment-related adverse events, graded using the Common Terminology Criteria for Adverse Events (CTCAE). These include infections other than SSI (for example Clostridioides difficile infection or pneumonia), allergic reactions, acute kidney injury, and other antibiotic-related toxicity.

    Time frame: From surgery through postoperative day 30

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Faul F, Erdfelder E, Lang AG, Buchner A. G*Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav Res Methods. 2007 May;39(2):175-91. doi: 10.3758/bf03193146. PubMed 17695343 ↗
  • Berrios-Torres SI, Umscheid CA, Bratzler DW, Leas B, Stone EC, Kelz RR, Reinke CE, Morgan S, Solomkin JS, Mazuski JE, Dellinger EP, Itani KMF, Berbari EF, Segreti J, Parvizi J, Blanchard J, Allen G, Kluytmans JAJW, Donlan R, Schecter WP; Healthcare Infection Control Practices Advisory Committee. Centers for Disease Control and Prevention Guideline for the Prevention of Surgical Site Infection, 2017. JAMA Surg. 2017 Aug 1;152(8):784-791. doi: 10.1001/jamasurg.2017.0904. PubMed 28467526 ↗
  • Haidar YM, Tripathi PB, Tjoa T, Walia S, Zhang L, Chen Y, Nguyen DV, Mahboubi H, Armstrong WB, Goddard JA. Antibiotic prophylaxis in clean-contaminated head and neck cases with microvascular free flap reconstruction: A systematic review and meta-analysis. Head Neck. 2018 Feb;40(2):417-427. doi: 10.1002/hed.24988. Epub 2017 Oct 30. PubMed 29083525 ↗
  • Langerman A, Thisted R, Hohmann S, Howell M. Antibiotic and Duration of Perioperative Prophylaxis Predicts Surgical Site Infection in Head and Neck Surgery. Otolaryngol Head Neck Surg. 2016 Jun;154(6):1054-63. doi: 10.1177/0194599816634303. Epub 2016 Mar 1. PubMed 26932957 ↗
  • Lira RB, de Carvalho AY, de Carvalho GB, Lewis CM, Weber RS, Kowalski LP. Quality assessment in head and neck oncologic surgery in a Brazilian cancer center compared with MD Anderson Cancer Center benchmarks. Head Neck. 2016 Jul;38(7):1002-7. doi: 10.1002/hed.24304. Epub 2015 Nov 28. PubMed 26614545 ↗

Individual participant data

Plan to share: Yes — De-identified individual participant data underlying the published results (the primary and secondary outcomes) will be shared on reasonable request. Data will be anonymized according to the Brazilian General Data Protection Law (LGPD) before release.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Beginning 6 months after publication of the primary results and ending 5 years after publication.

Access criteria: Data will be available to qualified researchers who submit a methodologically sound proposal, which the principal investigator will review. A data use agreement will be required, as well as approval from the A.C. Camargo Cancer Center Research Ethics Committee when applicable. Requests should be sent to the principal investigator.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2025 to primary completion in Jun 2025, 1 month.

Of 38 phase 3 interventional studies under Surgical Wound Infection, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 51. This study's 1 month is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 25, 2026
First posted
Oct 1, 2026
StartActual
May 29, 2025
Primary completionActual
Jun 30, 2025
CompletionEst.
May 30, 2028
Last update
Oct 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Title
Prophylactic Antibiotic Duration in Head and Neck Cancer Surgery: A Pragmatic, Open-Label, Randomized Superiority Trial (PROTECT-HN Trial)
Oct 5, 2026
Registered
First appeared on the registry
Oct 1, 2026
Show all 2 updates
  1. Oct 5, 2026
    Title Prophylactic Antibiotic Duration in Head and Neck Cancer Surgery: A Pragmatic, Open-Label, Randomized Superiority Trial (PROTECT-HN Trial)
    + 2 other changes: verification date and description
  2. Oct 1, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07851857
Lead sponsor
AC Camargo Cancer Center
Responsible party
Genival Barbosa de Carvalho (PhD, AC Camargo Cancer Center) — Principal investigator
First posted
Oct 1, 2026
Start date
May 29, 2025
Primary completion
Jun 30, 2025
Completion
May 30, 2028 (estimated)
Last update
Oct 5, 2026

Study contacts

Genival Barbosa de Carvalho, PhD
Contact
genival.carvalho@accamargo.org.br
55991447426
Renata Otoni Neiva, MD
Contact
renata.otoni@accamargo.org.br
55955835688

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion